IL305503A - Cancer treatment involving CAR engineered T cells and H-1 paravirus - Google Patents

Info

Publication number

IL305503A

IL305503A IL305503A IL30550323A IL305503A IL 305503 A IL305503 A IL 305503A IL 305503 A IL305503 A IL 305503A IL 30550323 A IL30550323 A IL 30550323A IL 305503 A IL305503 A IL 305503A

Authority

IL

Israel

Prior art keywords

cancer

cells

cell

car

antigen

Prior art date

2021-03-04

Links

• Espacenet
• Global Dossier
• Discuss

• 210000001744 T-lymphocyte Anatomy 0.000 title claims description 123
• 241000702620 H-1 parvovirus Species 0.000 title claims description 20
• 238000011275 oncology therapy Methods 0.000 title description 2
• 206010028980 Neoplasm Diseases 0.000 claims description 148
• 210000004027 cell Anatomy 0.000 claims description 142
• 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 120
• 239000000427 antigen Substances 0.000 claims description 69
• 108091007433 antigens Proteins 0.000 claims description 69
• 102000036639 antigens Human genes 0.000 claims description 69
• 201000011510 cancer Diseases 0.000 claims description 59
• 102000004127 Cytokines Human genes 0.000 claims description 29
• 108090000695 Cytokines Proteins 0.000 claims description 29
• 210000002865 immune cell Anatomy 0.000 claims description 26
• 244000309459 oncolytic virus Species 0.000 claims description 25
• 238000000034 method Methods 0.000 claims description 21
• 239000003814 drug Substances 0.000 claims description 19
• 239000003795 chemical substances by application Substances 0.000 claims description 18
• 230000000694 effects Effects 0.000 claims description 17
• 239000008194 pharmaceutical composition Substances 0.000 claims description 16
• 108090000623 proteins and genes Proteins 0.000 claims description 16
• -1 LewisY Proteins 0.000 claims description 15
• 230000004936 stimulating effect Effects 0.000 claims description 15
• 229940124597 therapeutic agent Drugs 0.000 claims description 15
• 206010033128 Ovarian cancer Diseases 0.000 claims description 13
• 206010009944 Colon cancer Diseases 0.000 claims description 12
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 12
• 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 11
• 102100023123 Mucin-16 Human genes 0.000 claims description 11
• 108010012236 Chemokines Proteins 0.000 claims description 8
• 102000019034 Chemokines Human genes 0.000 claims description 8
• 102000001301 EGF receptor Human genes 0.000 claims description 7
• 102100038083 Endosialin Human genes 0.000 claims description 7
• 238000001990 intravenous administration Methods 0.000 claims description 7
• 201000001441 melanoma Diseases 0.000 claims description 7
• 101000884275 Homo sapiens Endosialin Proteins 0.000 claims description 6
• 230000002163 immunogen Effects 0.000 claims description 5
• 230000001965 increasing effect Effects 0.000 claims description 5
• 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims description 4
• 102100026423 Adhesion G protein-coupled receptor E5 Human genes 0.000 claims description 4
• 108700012439 CA9 Proteins 0.000 claims description 4
• 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims description 4
• 102100038449 Claudin-6 Human genes 0.000 claims description 4
• 101150029707 ERBB2 gene Proteins 0.000 claims description 4
• 102100036939 G-protein coupled receptor 20 Human genes 0.000 claims description 4
• 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 4
• 101000718243 Homo sapiens Adhesion G protein-coupled receptor E5 Proteins 0.000 claims description 4
• 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 4
• 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 4
• 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 claims description 4
• 101000824971 Homo sapiens Sperm surface protein Sp17 Proteins 0.000 claims description 4
• 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 claims description 4
• 102100031413 L-dopachrome tautomerase Human genes 0.000 claims description 4
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
• 102100034256 Mucin-1 Human genes 0.000 claims description 4
• 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 claims description 4
• 102100025128 Olfactory receptor 51E2 Human genes 0.000 claims description 4
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
• 102100032364 Pannexin-3 Human genes 0.000 claims description 4
• 102100026181 Placenta-specific protein 1 Human genes 0.000 claims description 4
• 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims description 4
• 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims description 4
• 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 4
• 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 4
• 102100035764 Proteasome subunit beta type-9 Human genes 0.000 claims description 4
• 102100029337 Thyrotropin receptor Human genes 0.000 claims description 4
• 230000002601 intratumoral effect Effects 0.000 claims description 4
• 201000005202 lung cancer Diseases 0.000 claims description 4
• 208000020816 lung neoplasm Diseases 0.000 claims description 4
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
• 201000002528 pancreatic cancer Diseases 0.000 claims description 4
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
• 230000002046 pro-migratory effect Effects 0.000 claims description 4
• 230000035755 proliferation Effects 0.000 claims description 4
• 102100023003 Ankyrin repeat domain-containing protein 30A Human genes 0.000 claims description 3
• 102000030431 Asparaginyl endopeptidase Human genes 0.000 claims description 3
• 206010005003 Bladder cancer Diseases 0.000 claims description 3
• 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
• 206010006187 Breast cancer Diseases 0.000 claims description 3
• 208000026310 Breast neoplasm Diseases 0.000 claims description 3
• 108010058905 CD44v6 antigen Proteins 0.000 claims description 3
• 102100025221 CD70 antigen Human genes 0.000 claims description 3
• 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 3
• 108010051152 Carboxylesterase Proteins 0.000 claims description 3
• 102000013392 Carboxylesterase Human genes 0.000 claims description 3
• 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
• 102100035167 Coiled-coil domain-containing protein 54 Human genes 0.000 claims description 3
• 108010044090 Ephrin-B2 Proteins 0.000 claims description 3
• 102100023721 Ephrin-B2 Human genes 0.000 claims description 3
• 102000010451 Folate receptor alpha Human genes 0.000 claims description 3
• 108050001931 Folate receptor alpha Proteins 0.000 claims description 3
• 102000010449 Folate receptor beta Human genes 0.000 claims description 3
• 108050001930 Folate receptor beta Proteins 0.000 claims description 3
• 102100021197 G-protein coupled receptor family C group 5 member D Human genes 0.000 claims description 3
• 101000757191 Homo sapiens Ankyrin repeat domain-containing protein 30A Proteins 0.000 claims description 3
• 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 3
• 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 3
• 101000737052 Homo sapiens Coiled-coil domain-containing protein 54 Proteins 0.000 claims description 3
• 101001040713 Homo sapiens G-protein coupled receptor family C group 5 member D Proteins 0.000 claims description 3
• 101001051490 Homo sapiens Neural cell adhesion molecule L1 Proteins 0.000 claims description 3
• 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 3
• 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
• 102000003735 Mesothelin Human genes 0.000 claims description 3
• 108090000015 Mesothelin Proteins 0.000 claims description 3
• 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims description 3
• KUIFHYPNNRVEKZ-VIJRYAKMSA-N O-(N-acetyl-alpha-D-galactosaminyl)-L-threonine Chemical compound OC(=O)[C@@H](N)[C@@H](C)O[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O KUIFHYPNNRVEKZ-VIJRYAKMSA-N 0.000 claims description 3
• 206010060862 Prostate cancer Diseases 0.000 claims description 3
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 3
• 206010038389 Renal cancer Diseases 0.000 claims description 3
• 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
• 102100038081 Signal transducer CD24 Human genes 0.000 claims description 3
• 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
• 239000002253 acid Substances 0.000 claims description 3
• 239000002246 antineoplastic agent Substances 0.000 claims description 3
• 108010055066 asparaginylendopeptidase Proteins 0.000 claims description 3
• 201000010881 cervical cancer Diseases 0.000 claims description 3
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 3
• 229940127089 cytotoxic agent Drugs 0.000 claims description 3
• 230000037433 frameshift Effects 0.000 claims description 3
• 206010017758 gastric cancer Diseases 0.000 claims description 3
• 230000002489 hematologic effect Effects 0.000 claims description 3
• 230000002401 inhibitory effect Effects 0.000 claims description 3
• 230000000968 intestinal effect Effects 0.000 claims description 3
• 201000010982 kidney cancer Diseases 0.000 claims description 3
• 201000007270 liver cancer Diseases 0.000 claims description 3
• 208000014018 liver neoplasm Diseases 0.000 claims description 3
• 201000011549 stomach cancer Diseases 0.000 claims description 3
• 230000001256 tonic effect Effects 0.000 claims description 3
• 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
• 102100023635 Alpha-fetoprotein Human genes 0.000 claims description 2
• 101100095895 Drosophila melanogaster sle gene Proteins 0.000 claims description 2
• 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 claims description 2
• 101001014223 Homo sapiens MAPK/MAK/MRK overlapping kinase Proteins 0.000 claims description 2
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
• 101000733249 Homo sapiens Tumor suppressor ARF Proteins 0.000 claims description 2
• 101710123134 Ice-binding protein Proteins 0.000 claims description 2
• 101710082837 Ice-structuring protein Proteins 0.000 claims description 2
• 108010028275 Leukocyte Elastase Proteins 0.000 claims description 2
• 102100031520 MAPK/MAK/MRK overlapping kinase Human genes 0.000 claims description 2
• 101100182730 Mus musculus Ly6k gene Proteins 0.000 claims description 2
• 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 claims description 2
• 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 claims description 2
• 108010034949 Thyroglobulin Proteins 0.000 claims description 2
• 102100033254 Tumor suppressor ARF Human genes 0.000 claims description 2
• 101710107540 Type-2 ice-structuring protein Proteins 0.000 claims description 2
• 230000000977 initiatory effect Effects 0.000 claims description 2
• 210000000130 stem cell Anatomy 0.000 claims description 2
• 229960002175 thyroglobulin Drugs 0.000 claims description 2
• 101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 claims 2
• 208000029742 colonic neoplasm Diseases 0.000 claims 2
• 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 2
• 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
• LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims 1
• 108060003355 ADRB3 Proteins 0.000 claims 1
• 102000017918 ADRB3 Human genes 0.000 claims 1
• 102100027522 Baculoviral IAP repeat-containing protein 7 Human genes 0.000 claims 1
• 108010062540 Chorionic Gonadotropin Proteins 0.000 claims 1
• 102000011022 Chorionic Gonadotropin Human genes 0.000 claims 1
• 102100027417 Cytochrome P450 1B1 Human genes 0.000 claims 1
• 102000012804 EPCAM Human genes 0.000 claims 1
• 101150084967 EPCAM gene Proteins 0.000 claims 1
• 101710088083 Glomulin Proteins 0.000 claims 1
• 108010007712 Hepatitis A Virus Cellular Receptor 1 Proteins 0.000 claims 1
• 102000007343 Hepatitis A Virus Cellular Receptor 1 Human genes 0.000 claims 1
• 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 claims 1
• 101000936083 Homo sapiens Baculoviral IAP repeat-containing protein 7 Proteins 0.000 claims 1
• 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 1
• 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 1
• 101000882898 Homo sapiens Claudin-6 Proteins 0.000 claims 1
• 101000725164 Homo sapiens Cytochrome P450 1B1 Proteins 0.000 claims 1
• 101001071355 Homo sapiens G-protein coupled receptor 20 Proteins 0.000 claims 1
• 101000721757 Homo sapiens Olfactory receptor 51E2 Proteins 0.000 claims 1
• 101000589399 Homo sapiens Pannexin-3 Proteins 0.000 claims 1
• 101000691463 Homo sapiens Placenta-specific protein 1 Proteins 0.000 claims 1
• 101001064779 Homo sapiens Plexin domain-containing protein 2 Proteins 0.000 claims 1
• 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 1
• 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 1
• 101000772267 Homo sapiens Thyrotropin receptor Proteins 0.000 claims 1
• 101000808105 Homo sapiens Uroplakin-2 Proteins 0.000 claims 1
• 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 1
• 101710093778 L-dopachrome tautomerase Proteins 0.000 claims 1
• 102000016799 Leukocyte elastase Human genes 0.000 claims 1
• 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 1
• 102100021768 Phosphoserine aminotransferase Human genes 0.000 claims 1
• 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 claims 1
• 102100031889 Plexin domain-containing protein 2 Human genes 0.000 claims 1
• 101710173694 Short transient receptor potential channel 2 Proteins 0.000 claims 1
• 101150057140 TACSTD1 gene Proteins 0.000 claims 1
• 108010032166 TARP Proteins 0.000 claims 1
• 102000009843 Thyroglobulin Human genes 0.000 claims 1
• 102100038851 Uroplakin-2 Human genes 0.000 claims 1
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
• 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims 1
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
• 229940084986 human chorionic gonadotropin Drugs 0.000 claims 1
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
• 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
• 101150047061 tag-72 gene Proteins 0.000 claims 1
• 241000700605 Viruses Species 0.000 description 40
• 238000011282 treatment Methods 0.000 description 40
• 210000001519 tissue Anatomy 0.000 description 29
• 230000008595 infiltration Effects 0.000 description 22
• 238000001764 infiltration Methods 0.000 description 22
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
• 238000002560 therapeutic procedure Methods 0.000 description 19
• 230000014509 gene expression Effects 0.000 description 18
• 241000125945 Protoparvovirus Species 0.000 description 16
• 230000011664 signaling Effects 0.000 description 16
• 201000010099 disease Diseases 0.000 description 15
• 241000282414 Homo sapiens Species 0.000 description 14
• 230000004913 activation Effects 0.000 description 14
• 230000028993 immune response Effects 0.000 description 14
• 230000001225 therapeutic effect Effects 0.000 description 14
• 238000009169 immunotherapy Methods 0.000 description 12
• 238000002648 combination therapy Methods 0.000 description 11
• 239000003085 diluting agent Substances 0.000 description 11
• IPJDHSYCSQAODE-UHFFFAOYSA-N 5-chloromethylfluorescein diacetate Chemical compound O1C(=O)C2=CC(CCl)=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 IPJDHSYCSQAODE-UHFFFAOYSA-N 0.000 description 10
• 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 10
• 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 10
• 238000002360 preparation method Methods 0.000 description 10
• 108090000765 processed proteins & peptides Proteins 0.000 description 10
• 238000002659 cell therapy Methods 0.000 description 9
• 239000002609 medium Substances 0.000 description 9
• 230000004044 response Effects 0.000 description 9
• 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 8
• 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 8
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 8
• 238000002955 isolation Methods 0.000 description 8
• 239000000203 mixture Substances 0.000 description 8
• 229920001184 polypeptide Polymers 0.000 description 8
• 102000004196 processed proteins & peptides Human genes 0.000 description 8
• 238000002512 chemotherapy Methods 0.000 description 7
• 208000037966 cold tumor Diseases 0.000 description 7
• 150000001875 compounds Chemical class 0.000 description 7
• 108020001507 fusion proteins Proteins 0.000 description 7
• 102000037865 fusion proteins Human genes 0.000 description 7
• 230000001939 inductive effect Effects 0.000 description 7
• 230000004068 intracellular signaling Effects 0.000 description 7
• 210000004698 lymphocyte Anatomy 0.000 description 7
• 102000039446 nucleic acids Human genes 0.000 description 7
• 108020004707 nucleic acids Proteins 0.000 description 7
• 150000007523 nucleic acids Chemical class 0.000 description 7
• 102000004169 proteins and genes Human genes 0.000 description 7
• 230000000735 allogeneic effect Effects 0.000 description 6
• 238000013459 approach Methods 0.000 description 6
• 230000001413 cellular effect Effects 0.000 description 6
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 6
• 239000003937 drug carrier Substances 0.000 description 6
• 238000005516 engineering process Methods 0.000 description 6
• 239000002245 particle Substances 0.000 description 6
• 239000000546 pharmaceutical excipient Substances 0.000 description 6
• 230000000069 prophylactic effect Effects 0.000 description 6
• 102000005962 receptors Human genes 0.000 description 6
• 108020003175 receptors Proteins 0.000 description 6
• 230000003612 virological effect Effects 0.000 description 6
• 238000011357 CAR T-cell therapy Methods 0.000 description 5
• 108060006698 EGF receptor Proteins 0.000 description 5
• 206010025323 Lymphomas Diseases 0.000 description 5
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 5
• 206010027476 Metastases Diseases 0.000 description 5
• 241001465754 Metazoa Species 0.000 description 5
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
• 238000004458 analytical method Methods 0.000 description 5
• 210000003719 b-lymphocyte Anatomy 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• 210000004369 blood Anatomy 0.000 description 5
• 239000008280 blood Substances 0.000 description 5
• 230000012292 cell migration Effects 0.000 description 5
• 238000006243 chemical reaction Methods 0.000 description 5
• 210000004443 dendritic cell Anatomy 0.000 description 5
• 230000002708 enhancing effect Effects 0.000 description 5
• 208000037967 hot tumor Diseases 0.000 description 5
• 210000000987 immune system Anatomy 0.000 description 5
• 230000001976 improved effect Effects 0.000 description 5
• 238000000338 in vitro Methods 0.000 description 5
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 5
• 230000008685 targeting Effects 0.000 description 5
• 238000012360 testing method Methods 0.000 description 5
• 210000004881 tumor cell Anatomy 0.000 description 5
• 230000003827 upregulation Effects 0.000 description 5
• 239000013598 vector Substances 0.000 description 5
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
• 241000283690 Bos taurus Species 0.000 description 4
• 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 4
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 4
• 108010002350 Interleukin-2 Proteins 0.000 description 4
• 206010027457 Metastases to liver Diseases 0.000 description 4
• 241000700159 Rattus Species 0.000 description 4
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 4
• 230000001093 anti-cancer Effects 0.000 description 4
• 210000001072 colon Anatomy 0.000 description 4
• 208000035475 disorder Diseases 0.000 description 4
• 208000015181 infectious disease Diseases 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 210000004185 liver Anatomy 0.000 description 4
• 230000003211 malignant effect Effects 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• 230000009401 metastasis Effects 0.000 description 4
• 210000000822 natural killer cell Anatomy 0.000 description 4
• 210000005259 peripheral blood Anatomy 0.000 description 4
• 239000011886 peripheral blood Substances 0.000 description 4
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
• 238000001959 radiotherapy Methods 0.000 description 4
• 238000002271 resection Methods 0.000 description 4
• 239000000243 solution Substances 0.000 description 4
• 238000001356 surgical procedure Methods 0.000 description 4
• 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 3
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 3
• 102100034159 Beta-3 adrenergic receptor Human genes 0.000 description 3
• 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 3
• 102100026094 C-type lectin domain family 12 member A Human genes 0.000 description 3
• 101710188619 C-type lectin domain family 12 member A Proteins 0.000 description 3
• 102100027207 CD27 antigen Human genes 0.000 description 3
• 108010021064 CTLA-4 Antigen Proteins 0.000 description 3
• 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
• 108090000229 Claudin-6 Proteins 0.000 description 3
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 3
• 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 3
• 101710108873 G-protein coupled receptor 20 Proteins 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 3
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 3
• 101000780539 Homo sapiens Beta-3 adrenergic receptor Proteins 0.000 description 3
• 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 3
• 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 3
• 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 description 3
• 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 3
• 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 description 3
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• 241000699666 Mus <mouse, genus> Species 0.000 description 3
• 102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 description 3
• 108091028043 Nucleic acid sequence Proteins 0.000 description 3
• 101710187841 Olfactory receptor 51E2 Proteins 0.000 description 3
• 101710165197 Pannexin-3 Proteins 0.000 description 3
• 108050005093 Placenta-specific protein 1 Proteins 0.000 description 3
• 101710164680 Platelet-derived growth factor receptor beta Proteins 0.000 description 3
• 101710120463 Prostate stem cell antigen Proteins 0.000 description 3
• 102100038358 Prostate-specific antigen Human genes 0.000 description 3
• 241000283984 Rodentia Species 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 3
• 108090000253 Thyrotropin Receptors Proteins 0.000 description 3
• 102000013532 Uroplakin II Human genes 0.000 description 3
• 108010065940 Uroplakin II Proteins 0.000 description 3
• 108091008605 VEGF receptors Proteins 0.000 description 3
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 3
• 230000000259 anti-tumor effect Effects 0.000 description 3
• 230000030741 antigen processing and presentation Effects 0.000 description 3
• 210000000612 antigen-presenting cell Anatomy 0.000 description 3
• 230000006907 apoptotic process Effects 0.000 description 3
• 238000010241 blood sampling Methods 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 238000004113 cell culture Methods 0.000 description 3
• 230000001086 cytosolic effect Effects 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 230000004069 differentiation Effects 0.000 description 3
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 3
• 108010051081 dopachrome isomerase Proteins 0.000 description 3
• 238000000605 extraction Methods 0.000 description 3
• 108010072257 fibroblast activation protein alpha Proteins 0.000 description 3
• 230000006870 function Effects 0.000 description 3
• 230000001506 immunosuppresive effect Effects 0.000 description 3
• 230000006698 induction Effects 0.000 description 3
• 230000009545 invasion Effects 0.000 description 3
• 230000036210 malignancy Effects 0.000 description 3
• 239000002953 phosphate buffered saline Substances 0.000 description 3
• 239000003755 preservative agent Substances 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 230000002829 reductive effect Effects 0.000 description 3
• 239000007787 solid Substances 0.000 description 3
• 239000000126 substance Substances 0.000 description 3
• 210000001550 testis Anatomy 0.000 description 3
• 238000001890 transfection Methods 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• 238000012384 transportation and delivery Methods 0.000 description 3
• 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 3
• 235000012431 wafers Nutrition 0.000 description 3
• LTHJXDSHSVNJKG-UHFFFAOYSA-N 2-[2-[2-[2-(2-methylprop-2-enoyloxy)ethoxy]ethoxy]ethoxy]ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOCCOCCOCCOC(=O)C(C)=C LTHJXDSHSVNJKG-UHFFFAOYSA-N 0.000 description 2
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
• 101710109924 A-kinase anchor protein 4 Proteins 0.000 description 2
• 208000006678 Abdominal Neoplasms Diseases 0.000 description 2
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
• 102100026402 Adhesion G protein-coupled receptor E2 Human genes 0.000 description 2
• 102100037982 Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A Human genes 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 2
• 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
• 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 2
• 102100029390 CMRF35-like molecule 1 Human genes 0.000 description 2
• 108091033409 CRISPR Proteins 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 2
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
• 108020004414 DNA Proteins 0.000 description 2
• 230000004543 DNA replication Effects 0.000 description 2
• 241000283073 Equus caballus Species 0.000 description 2
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
• 102100031507 Fc receptor-like protein 5 Human genes 0.000 description 2
• 241000282326 Felis catus Species 0.000 description 2
• 201000008808 Fibrosarcoma Diseases 0.000 description 2
• 229920001917 Ficoll Polymers 0.000 description 2
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
• 102000010956 Glypican Human genes 0.000 description 2
• 108050001154 Glypican Proteins 0.000 description 2
• 108050007237 Glypican-3 Proteins 0.000 description 2
• 208000009329 Graft vs Host Disease Diseases 0.000 description 2
• 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 2
• 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 2
• 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
• 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 2
• 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 2
• 101000990055 Homo sapiens CMRF35-like molecule 1 Proteins 0.000 description 2
• 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 description 2
• 101000814512 Homo sapiens X antigen family member 1 Proteins 0.000 description 2
• 241000701806 Human papillomavirus Species 0.000 description 2
• 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 2
• 102100029616 Immunoglobulin lambda-like polypeptide 1 Human genes 0.000 description 2
• 101710107067 Immunoglobulin lambda-like polypeptide 1 Proteins 0.000 description 2
• 101710128560 Initiator protein NS1 Proteins 0.000 description 2
• 108010002616 Interleukin-5 Proteins 0.000 description 2
• 108010002586 Interleukin-7 Proteins 0.000 description 2
• 102100025586 Leukocyte immunoglobulin-like receptor subfamily A member 2 Human genes 0.000 description 2
• 101710196509 Leukocyte immunoglobulin-like receptor subfamily A member 2 Proteins 0.000 description 2
• 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 description 2
• 102100033486 Lymphocyte antigen 75 Human genes 0.000 description 2
• 101710157884 Lymphocyte antigen 75 Proteins 0.000 description 2
• 108050008953 Melanoma-associated antigen Proteins 0.000 description 2
• 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 2
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
• 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 2
• 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 2
• 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
• 101710144127 Non-structural protein 1 Proteins 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 241000701945 Parvoviridae Species 0.000 description 2
• 241001494479 Pecora Species 0.000 description 2
• 241000009328 Perro Species 0.000 description 2
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
• 102100035703 Prostatic acid phosphatase Human genes 0.000 description 2
• 102100037686 Protein SSX2 Human genes 0.000 description 2
• 101710149284 Protein SSX2 Proteins 0.000 description 2
• 102100038098 Protein-glutamine gamma-glutamyltransferase 5 Human genes 0.000 description 2
• 108010024221 Proto-Oncogene Proteins c-bcr Proteins 0.000 description 2
• 102000015690 Proto-Oncogene Proteins c-bcr Human genes 0.000 description 2
• 241000984817 Rat minute virus Species 0.000 description 2
• 108010045108 Receptor for Advanced Glycation End Products Proteins 0.000 description 2
• 102000005622 Receptor for Advanced Glycation End Products Human genes 0.000 description 2
• 102100027610 Rho-related GTP-binding protein RhoC Human genes 0.000 description 2
• 206010039491 Sarcoma Diseases 0.000 description 2
• 206010041067 Small cell lung cancer Diseases 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
• 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 description 2
• 241000282898 Sus scrofa Species 0.000 description 2
• 230000006044 T cell activation Effects 0.000 description 2
• 230000024932 T cell mediated immunity Effects 0.000 description 2
• 108091008874 T cell receptors Proteins 0.000 description 2
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
• 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 2
• 108010066342 Virus Receptors Proteins 0.000 description 2
• 102100022748 Wilms tumor protein Human genes 0.000 description 2
• 101710127857 Wilms tumor protein Proteins 0.000 description 2
• 102100039490 X antigen family member 1 Human genes 0.000 description 2
• 102100026497 Zinc finger protein 654 Human genes 0.000 description 2
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 230000003044 adaptive effect Effects 0.000 description 2
• 108010034034 alpha-1,6-mannosylglycoprotein beta 1,6-N-acetylglucosaminyltransferase Proteins 0.000 description 2
• 230000004888 barrier function Effects 0.000 description 2
• 239000011324 bead Substances 0.000 description 2
• 230000015572 biosynthetic process Effects 0.000 description 2
• 210000004204 blood vessel Anatomy 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 230000036755 cellular response Effects 0.000 description 2
• 230000005754 cellular signaling Effects 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 210000000349 chromosome Anatomy 0.000 description 2
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
• 229920001577 copolymer Polymers 0.000 description 2
• 230000000139 costimulatory effect Effects 0.000 description 2
• 231100000135 cytotoxicity Toxicity 0.000 description 2
• 230000003013 cytotoxicity Effects 0.000 description 2
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 229940079593 drug Drugs 0.000 description 2
• 239000012636 effector Substances 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 108091008790 ephrin type A receptors Proteins 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 229960002949 fluorouracil Drugs 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 150000002270 gangliosides Chemical class 0.000 description 2
• 208000024908 graft versus host disease Diseases 0.000 description 2
• 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 2
• 230000006058 immune tolerance Effects 0.000 description 2
• 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 210000004964 innate lymphoid cell Anatomy 0.000 description 2
• JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
• 108010025001 leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 description 2
• 239000003446 ligand Substances 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 2
• 201000011216 nasopharynx carcinoma Diseases 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 208000020668 oropharyngeal carcinoma Diseases 0.000 description 2
• 201000006958 oropharynx cancer Diseases 0.000 description 2
• 230000007170 pathology Effects 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 230000002688 persistence Effects 0.000 description 2
• 239000013600 plasmid vector Substances 0.000 description 2
• 239000004033 plastic Substances 0.000 description 2
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 230000002035 prolonged effect Effects 0.000 description 2
• 108010043671 prostatic acid phosphatase Proteins 0.000 description 2
• 230000001681 protective effect Effects 0.000 description 2
• 230000005855 radiation Effects 0.000 description 2
• GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
• 229960004622 raloxifene Drugs 0.000 description 2
• 210000003289 regulatory T cell Anatomy 0.000 description 2
• 230000004043 responsiveness Effects 0.000 description 2
• 108010056030 retronectin Proteins 0.000 description 2
• 108010073531 rhoC GTP-Binding Protein Proteins 0.000 description 2
• 238000009097 single-agent therapy Methods 0.000 description 2
• 208000000587 small cell lung carcinoma Diseases 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 230000002195 synergetic effect Effects 0.000 description 2
• 238000011287 therapeutic dose Methods 0.000 description 2
• 108010078373 tisagenlecleucel Proteins 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 238000010361 transduction Methods 0.000 description 2
• 230000026683 transduction Effects 0.000 description 2
• 108010058721 transglutaminase 5 Proteins 0.000 description 2
• 238000002255 vaccination Methods 0.000 description 2
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
• DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 1
• TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
• 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
• 102100022907 Acrosin-binding protein Human genes 0.000 description 1
• 101710107749 Acrosin-binding protein Proteins 0.000 description 1
• 206010000830 Acute leukaemia Diseases 0.000 description 1
• 101710096292 Adhesion G protein-coupled receptor E2 Proteins 0.000 description 1
• 102100032187 Androgen receptor Human genes 0.000 description 1
• 102000009840 Angiopoietins Human genes 0.000 description 1
• 108010009906 Angiopoietins Proteins 0.000 description 1
• 108010083359 Antigen Receptors Proteins 0.000 description 1
• 102000006306 Antigen Receptors Human genes 0.000 description 1
• 206010002961 Aplasia Diseases 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 108091008875 B cell receptors Proteins 0.000 description 1
• 208000004736 B-Cell Leukemia Diseases 0.000 description 1
• 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
• 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 1
• 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 1
• 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
• 108091007065 BIRCs Proteins 0.000 description 1
• 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 241000283725 Bos Species 0.000 description 1
• 206010006143 Brain stem glioma Diseases 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
• 102100038078 CD276 antigen Human genes 0.000 description 1
• 108010029697 CD40 Ligand Proteins 0.000 description 1
• 101150013553 CD40 gene Proteins 0.000 description 1
• 102100032937 CD40 ligand Human genes 0.000 description 1
• 229940126074 CDK kinase inhibitor Drugs 0.000 description 1
• 238000010354 CRISPR gene editing Methods 0.000 description 1
• 101100518995 Caenorhabditis elegans pax-3 gene Proteins 0.000 description 1
• KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
• 102100039510 Cancer/testis antigen 2 Human genes 0.000 description 1
• 101710120595 Cancer/testis antigen 2 Proteins 0.000 description 1
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 102000004225 Cathepsin B Human genes 0.000 description 1
• 108090000712 Cathepsin B Proteins 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 101710181340 Chaperone protein DnaK2 Proteins 0.000 description 1
• MKQWTWSXVILIKJ-LXGUWJNJSA-N Chlorozotocin Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC(=O)N(N=O)CCCl MKQWTWSXVILIKJ-LXGUWJNJSA-N 0.000 description 1
• 102100030886 Complement receptor type 1 Human genes 0.000 description 1
• 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
• 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
• 102000016736 Cyclin Human genes 0.000 description 1
• 108050006400 Cyclin Proteins 0.000 description 1
• 108010068192 Cyclin A Proteins 0.000 description 1
• 102100025191 Cyclin-A2 Human genes 0.000 description 1
• 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
• 102000018832 Cytochromes Human genes 0.000 description 1
• 108010052832 Cytochromes Proteins 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• 230000005778 DNA damage Effects 0.000 description 1
• 231100000277 DNA damage Toxicity 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• 108010092160 Dactinomycin Proteins 0.000 description 1
• 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
• WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 102100031334 Elongation factor 2 Human genes 0.000 description 1
• 206010014733 Endometrial cancer Diseases 0.000 description 1
• 206010014759 Endometrial neoplasm Diseases 0.000 description 1
• 101710144543 Endosialin Proteins 0.000 description 1
• 206010014967 Ependymoma Diseases 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000283074 Equus asinus Species 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 102000015212 Fas Ligand Protein Human genes 0.000 description 1
• 108010039471 Fas Ligand Protein Proteins 0.000 description 1
• 102000003817 Fos-related antigen 1 Human genes 0.000 description 1
• 108090000123 Fos-related antigen 1 Proteins 0.000 description 1
• 102100020997 Fractalkine Human genes 0.000 description 1
• 102000027583 GPCRs class C Human genes 0.000 description 1
• 108091008882 GPCRs class C Proteins 0.000 description 1
• 102100039554 Galectin-8 Human genes 0.000 description 1
• 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 102000006771 Gonadotropins Human genes 0.000 description 1
• 108010086677 Gonadotropins Proteins 0.000 description 1
• 102100021186 Granulysin Human genes 0.000 description 1
• 101710168479 Granulysin Proteins 0.000 description 1
• 108060005986 Granzyme Proteins 0.000 description 1
• 102000001398 Granzyme Human genes 0.000 description 1
• 102000009465 Growth Factor Receptors Human genes 0.000 description 1
• 108010009202 Growth Factor Receptors Proteins 0.000 description 1
• 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 1
• 206010066476 Haematological malignancy Diseases 0.000 description 1
• 101710178419 Heat shock protein 70 2 Proteins 0.000 description 1
• 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
• 101000718211 Homo sapiens Adhesion G protein-coupled receptor E2 Proteins 0.000 description 1
• 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 description 1
• 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
• 101000884279 Homo sapiens CD276 antigen Proteins 0.000 description 1
• 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 description 1
• 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 description 1
• 101000854520 Homo sapiens Fractalkine Proteins 0.000 description 1
• 101000608769 Homo sapiens Galectin-8 Proteins 0.000 description 1
• 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
• 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
• 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
• 101000873927 Homo sapiens Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 description 1
• 101000894428 Homo sapiens Transcriptional repressor CTCFL Proteins 0.000 description 1
• 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 1
• 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
• 101001052849 Homo sapiens Tyrosine-protein kinase Fer Proteins 0.000 description 1
• 101001047681 Homo sapiens Tyrosine-protein kinase Lck Proteins 0.000 description 1
• 108010031794 IGF Type 1 Receptor Proteins 0.000 description 1
• MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
• 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 description 1
• 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 1
• 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
• 102000003814 Interleukin-10 Human genes 0.000 description 1
• 108090000174 Interleukin-10 Proteins 0.000 description 1
• 102000004553 Interleukin-11 Receptors Human genes 0.000 description 1
• 108010017521 Interleukin-11 Receptors Proteins 0.000 description 1
• 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 description 1
• 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 description 1
• 108090001005 Interleukin-6 Proteins 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• 102000017578 LAG3 Human genes 0.000 description 1
• 101150030213 Lag3 gene Proteins 0.000 description 1
• 241000713666 Lentivirus Species 0.000 description 1
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
• 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 1
• 108700012912 MYCN Proteins 0.000 description 1
• 101150022024 MYCN gene Proteins 0.000 description 1
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• 101100518997 Mus musculus Pax3 gene Proteins 0.000 description 1
• 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
• 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
• 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
• 102000048850 Neoplasm Genes Human genes 0.000 description 1
• 108700019961 Neoplasm Genes Proteins 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 102100033174 Neutrophil elastase Human genes 0.000 description 1
• 101800000512 Non-structural protein 1 Proteins 0.000 description 1
• 201000010133 Oligodendroglioma Diseases 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 108700026244 Open Reading Frames Proteins 0.000 description 1
• 102100040891 Paired box protein Pax-3 Human genes 0.000 description 1
• 101710149060 Paired box protein Pax-3 Proteins 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 108010077519 Peptide Elongation Factor 2 Proteins 0.000 description 1
• 102000004503 Perforin Human genes 0.000 description 1
• 108010056995 Perforin Proteins 0.000 description 1
• KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
• 241000577979 Peromyscus spicilegus Species 0.000 description 1
• 206010035603 Pleural mesothelioma Diseases 0.000 description 1
• 102100037891 Plexin domain-containing protein 1 Human genes 0.000 description 1
• 108050009432 Plexin domain-containing protein 1 Proteins 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
• 108010006700 Receptor Tyrosine Kinase-like Orphan Receptors Proteins 0.000 description 1
• 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
• 239000008156 Ringer's lactate solution Substances 0.000 description 1
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
• 108020004682 Single-Stranded DNA Proteins 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
• 102000004584 Somatomedin Receptors Human genes 0.000 description 1
• 108010017622 Somatomedin Receptors Proteins 0.000 description 1
• 102100022441 Sperm surface protein Sp17 Human genes 0.000 description 1
• 101710185775 Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 description 1
• 101800001271 Surface protein Proteins 0.000 description 1
• 108010002687 Survivin Proteins 0.000 description 1
• 230000005867 T cell response Effects 0.000 description 1
• 238000010459 TALEN Methods 0.000 description 1
• 108700012920 TNF Proteins 0.000 description 1
• 108010017842 Telomerase Proteins 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• 206010057644 Testis cancer Diseases 0.000 description 1
• 102100033504 Thyroglobulin Human genes 0.000 description 1
• 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
• 102100021393 Transcriptional repressor CTCFL Human genes 0.000 description 1
• 101710081844 Transmembrane protease serine 2 Proteins 0.000 description 1
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
• 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
• 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
• 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
• 102000003425 Tyrosinase Human genes 0.000 description 1
• 108060008724 Tyrosinase Proteins 0.000 description 1
• 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 description 1
• 101710098624 Tyrosine-protein kinase ABL1 Proteins 0.000 description 1
• 102100024537 Tyrosine-protein kinase Fer Human genes 0.000 description 1
• 102100024036 Tyrosine-protein kinase Lck Human genes 0.000 description 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• IHGLINDYFMDHJG-UHFFFAOYSA-N [2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanone Chemical compound C1=CC(OC)=CC=C1C(CCC1=CC=CC=C11)=C1C(=O)C(C=C1)=CC=C1OCCN1CCCC1 IHGLINDYFMDHJG-UHFFFAOYSA-N 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 230000001464 adherent effect Effects 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 208000037842 advanced-stage tumor Diseases 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 108700025316 aldesleukin Proteins 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 229960003896 aminopterin Drugs 0.000 description 1
• 201000007538 anal carcinoma Diseases 0.000 description 1
• 108010080146 androgen receptors Proteins 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000006023 anti-tumor response Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 238000009175 antibody therapy Methods 0.000 description 1
• 230000007416 antiviral immune response Effects 0.000 description 1
• 239000003886 aromatase inhibitor Substances 0.000 description 1
• 229940046844 aromatase inhibitors Drugs 0.000 description 1
• 210000001367 artery Anatomy 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 229950002916 avelumab Drugs 0.000 description 1
• 229950009579 axicabtagene ciloleucel Drugs 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• 210000003651 basophil Anatomy 0.000 description 1
• 229960000686 benzalkonium chloride Drugs 0.000 description 1
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 239000000560 biocompatible material Substances 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 239000000090 biomarker Substances 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 108010064866 biozym Proteins 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
• 229940127093 camptothecin Drugs 0.000 description 1
• VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
• 238000002619 cancer immunotherapy Methods 0.000 description 1
• 208000035269 cancer or benign tumor Diseases 0.000 description 1
• 210000000234 capsid Anatomy 0.000 description 1
• 101150058049 car gene Proteins 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 201000003959 cecum carcinoma Diseases 0.000 description 1
• 230000025084 cell cycle arrest Effects 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000006721 cell death pathway Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000006037 cell lysis Effects 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 229960001480 chlorozotocin Drugs 0.000 description 1
• 208000024207 chronic leukemia Diseases 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 201000010989 colorectal carcinoma Diseases 0.000 description 1
• 230000007748 combinatorial effect Effects 0.000 description 1
• 238000002591 computed tomography Methods 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
• 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• 229960000640 dactinomycin Drugs 0.000 description 1
• 235000013365 dairy product Nutrition 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 229960000975 daunorubicin Drugs 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 238000000432 density-gradient centrifugation Methods 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
• 229950004203 droloxifene Drugs 0.000 description 1
• 238000002651 drug therapy Methods 0.000 description 1
• FSIRXIHZBIXHKT-MHTVFEQDSA-N edatrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
• 229950006700 edatrexate Drugs 0.000 description 1
• 210000003162 effector t lymphocyte Anatomy 0.000 description 1
• VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 210000003979 eosinophil Anatomy 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 238000013401 experimental design Methods 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 239000012997 ficoll-paque Substances 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 229960000390 fludarabine Drugs 0.000 description 1
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
• 238000012632 fluorescent imaging Methods 0.000 description 1
• 201000003444 follicular lymphoma Diseases 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 229960004783 fotemustine Drugs 0.000 description 1
• YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
• 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• PFJKOHUKELZMLE-VEUXDRLPSA-N ganglioside GM3 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(=O)CCCCCCCCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 PFJKOHUKELZMLE-VEUXDRLPSA-N 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 238000012239 gene modification Methods 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 230000005017 genetic modification Effects 0.000 description 1
• 235000013617 genetically modified food Nutrition 0.000 description 1
• 238000010362 genome editing Methods 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 239000002622 gonadotropin Substances 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 230000003394 haemopoietic effect Effects 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 210000002443 helper t lymphocyte Anatomy 0.000 description 1
• 201000005787 hematologic cancer Diseases 0.000 description 1
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
• 208000005252 hepatitis A Diseases 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
• 238000001794 hormone therapy Methods 0.000 description 1
• 230000028996 humoral immune response Effects 0.000 description 1
• 229940015872 ibandronate Drugs 0.000 description 1
• 229960000908 idarubicin Drugs 0.000 description 1
• 229960001101 ifosfamide Drugs 0.000 description 1
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 239000012642 immune effector Substances 0.000 description 1
• 108091008915 immune receptors Proteins 0.000 description 1
• 102000027596 immune receptors Human genes 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 238000002649 immunization Methods 0.000 description 1
• 230000003053 immunization Effects 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 238000003364 immunohistochemistry Methods 0.000 description 1
• 229940121354 immunomodulator Drugs 0.000 description 1
• 210000005008 immunosuppressive cell Anatomy 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 229940047122 interleukins Drugs 0.000 description 1
• 201000002313 intestinal cancer Diseases 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 229940008228 intravenous immunoglobulins Drugs 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 229960005386 ipilimumab Drugs 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 229940045426 kymriah Drugs 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
• 238000002595 magnetic resonance imaging Methods 0.000 description 1
• 210000005075 mammary gland Anatomy 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 229960001156 mitoxantrone Drugs 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 230000001400 myeloablative effect Effects 0.000 description 1
• 210000000066 myeloid cell Anatomy 0.000 description 1
• 108091008800 n-Myc Proteins 0.000 description 1
• 150000002790 naphthalenes Chemical class 0.000 description 1
• 210000000581 natural killer T-cell Anatomy 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 229960001420 nimustine Drugs 0.000 description 1
• VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
• 206010073131 oligoastrocytoma Diseases 0.000 description 1
• 230000000174 oncolytic effect Effects 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• 101710135378 pH 6 antigen Proteins 0.000 description 1
• 238000002559 palpation Methods 0.000 description 1
• 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
• 229960002621 pembrolizumab Drugs 0.000 description 1
• 229930192851 perforin Natural products 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 230000002572 peristaltic effect Effects 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 239000008024 pharmaceutical diluent Substances 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 150000003057 platinum Chemical class 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• 229920001515 polyalkylene glycol Polymers 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 229920001296 polysiloxane Polymers 0.000 description 1
• 238000010837 poor prognosis Methods 0.000 description 1
• 230000008092 positive effect Effects 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 210000004986 primary T-cell Anatomy 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 239000000047 product Substances 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• 229940087463 proleukin Drugs 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 229960002185 ranimustine Drugs 0.000 description 1
• 239000003642 reactive oxygen metabolite Substances 0.000 description 1
• 208000020615 rectal carcinoma Diseases 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 208000037922 refractory disease Diseases 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 238000012827 research and development Methods 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 125000005630 sialyl group Chemical group 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 238000011477 surgical intervention Methods 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 230000007761 synergistic anti-cancer Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 229960001603 tamoxifen Drugs 0.000 description 1
• 238000002626 targeted therapy Methods 0.000 description 1
• 238000010809 targeting technique Methods 0.000 description 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
• 229960001278 teniposide Drugs 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 239000012749 thinning agent Substances 0.000 description 1
• 229950007137 tisagenlecleucel Drugs 0.000 description 1
• 239000003104 tissue culture media Substances 0.000 description 1
• 230000008427 tissue turnover Effects 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 230000005945 translocation Effects 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 229950007217 tremelimumab Drugs 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 229950000212 trioxifene Drugs 0.000 description 1
• 230000005747 tumor angiogenesis Effects 0.000 description 1
• 239000000439 tumor marker Substances 0.000 description 1
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
• 230000037455 tumor specific immune response Effects 0.000 description 1
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
• 230000001173 tumoral effect Effects 0.000 description 1
• 238000002604 ultrasonography Methods 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
• 229960002066 vinorelbine Drugs 0.000 description 1
• 230000006648 viral gene expression Effects 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 229940053867 xeloda Drugs 0.000 description 1
• 229940045208 yescarta Drugs 0.000 description 1